Tuesday, Sep 17, 2024 · SEC filings
What the smart money revealed on Sep 17
665 insider filings came in. We hid 109 planned (10b5-1) sellers and 410 people whose filings were routine, like grants and tax withholding.
3 insiders at MBX Biosciences (MBX) bought $34M of stock
Roles: Director. Several insiders buying in the same few days is rare.
Terns Pharmaceuticals (TERN) Director Hongbo Lu bought $5M
476,190 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 4 checked quarters beat the typical stock 6 months later.
Zenas BioPharma (ZBIO) Director Hongbo Lu bought $1M
58,823 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 4 checked quarters beat the typical stock 6 months later.
Quanterix (QTRX) Director David Walt bought $625K
47,000 shares on the open market. Not a grant or an option exercise.
Treace Medical Concepts (TMCI) CEO John Treace bought $266K
50,000 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 3 checked quarters beat the typical stock 6 months later.
CompoSecure (GPGI) Director Michele Logan sold $125M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 2.04M shares directly.
UWM (UWMC) President and CEO Ishbia Mat sold $91.6M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day.
Liberty Global (LBTYA) Director Miranda Curtis sold $764K
Not marked as a planned 10b5-1 sale. Sold 61% of the shares they held directly. Still holds 24,099 shares.
Show 26 more real buys
Show 91 more real sales
13F season
Holdings as of Jun 30, 2024 were due Aug 14
54 funds have filed. 50 filed for the quarter before.
Biggest real insider buys, Sep 11–17
Open-market buys by officers and directors, filed in the 7 days up to Sep 17.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.